octreotide acetate

octreotide acetate

Sandostatin, Sandostatin LAR

Pharmacologic class: Somatostatin analog

Therapeutic class: Antidiarrheal

Pregnancy risk category B

Action

Suppresses secretion of serotonin, serotonin metabolites, and gastrohepatic peptides, increasing fluid and electrolyte absorption from GI tract. Also suppresses growth hormone, insulin, and glucagon.

Availability

Depot injection: 10 mg, 20 mg, 30 mg

Injection: 0.05 mg/ml, 0.1 mg/ml, and 0.5 mg/ml in 1-ml ampules; 0.2 mg/ml and 1 mg/ml in 5-ml vials

Indications and dosages

Diarrhea and flushing associated with carcinoid tumors

Adults: 100 to 600 mcg (Sandostatin) subcutaneously or I.V. daily in two to four divided doses for 2 weeks. Then, depending on response, 20 mg (LAR Depot) I.M. q 4 weeks for 2 months.

Diarrhea caused by vasoactive intestinal peptide tumors (VIPomas)

Adults: 200 to 300 mcg (Sandostatin) subcutaneously or I.V. daily in two to four divided doses for 2 weeks. Then, depending on response, 20 mg (LAR Depot) I.M. q 2 weeks for 2 months.

Acromegaly

Adults: 50 to 100 mcg (Sandostatin) subcutaneously or I.V. two or three times daily. Then, depending on response, 20 mg (LAR Depot) I.M. q 4 weeks for 3 months. Then adjust based on growth hormone levels.

Dosage adjustment

• Renal impairment

Off-label uses

• Dumping syndrome (postprandial hypotension)
• GI and pancreatic fistulas
• Variceal bleeding

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:
• gallbladder disease, renal impairment, hyperglycemia or hypoglycemia, fat malabsorption
• pregnant or breastfeeding patients
• children.

Administration

• When giving subcutaneously, rotate administration site with each injection.

Don't give LAR Depot I.V.
• Mix I.M. solution and inject deep into gluteal muscle over 3 minutes. Don't use deltoid.
• For I.V. administration, dilute in 50 to 200 ml of dextrose 5% in water or normal saline solution. Infuse over 15 to 30 minutes.
• Know that octreotide suppression test and octreotide scintigraphy may be done to determine if drug will aid carcinoid tumor treatment.
• Drug may be kept at room temperature for 2 weeks. Refrigerate ampules.

Adverse reactions

CNS: dizziness, drowsiness, fatigue, headache, weakness

CV: edema, bradycardia, conduction abnormalities, arrhythmias

EENT: vision disturbances

GI: nausea, vomiting, diarrhea, abdominal pain, cholelithiasis, fat malabsorption

Skin: flushing

Metabolic: hypothyroidism, hyperglycemia, hypoglycemia

Other: injection site pain

Interactions

Drug-drug.Cyclosporine: reduced cyclosporine blood level

Insulin, oral hypoglycemics: altered requirements for these drugs

Orally administered drugs: altered absorption of these drugs

Drug-diagnostic tests.Glucose: increased or decreased level

Hepatic enzymes: slightly increased levels

Schilling's test: abnormal results

Thyroxine, vitamin B12: decreased levels

Drug-food.Fats: altered octreotide absorption

Patient monitoring

• Assess bowel sounds and stool frequency and consistency.
• Monitor vital signs and fluid intake and output. Stay alert for dehydration or edema.
• Evaluate diabetic patient for hypoglycemia or hyperglycemia.
• Know that in women with active acromegaly, normalization of growth hormone and insulin-like growth factor-1 may restore fertility.

Patient teaching

• Tell patient being treated for carcinoid tumor to keep track of number of daily stools or flushing episodes.
• Instruct patient to weigh himself daily and report significant changes.
• Advise female with childbearing potential to use adequate contraception while taking drug.
• If patient will use drug at home, teach correct methods for injection, storage, and needle disposal.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

octreotide acetate

Sandostatin Endocrinology A depot somatostatin analogue with high GH affinity, resulting in a ↓ serum GH and amelioration of Sx in most Pts with acromegaly Indications (1) Reduction of growth hormone and IGF-1–insulin growth factor in acromegaly; (2) suppression of severe diarrhea and flushing associated with malignant carcinoid syndrome; (3) treatment of profuse watery diarrhea associated with VIPoma–vasoactive intestinal peptide tumor–and diarrhea and flushing associated with certain types of tumors; used to control of chemotherapy-induced diarrhea and flushing in Pts with metastatic carcinoid tumors and VIPomas, and for treating acromegaly; now also in clinical trials as a potential treatment of severe chemotherapy-induced diarrhea in Pts with colorectal CA

octreotide acetate

(ŏk′trē-ō-tīd)
A synthetic drug that mimics the action of somatostatin and is used in treating acromegaly, carcinoid tumors, vasoactive intestinal peptide tumors, pancreatitis, and gastrointestinal bleeding.
References in periodicals archive ?
Octreotide acetate microspheres as powder for parenteral use 20 mg vial or ampule
Drug profiles described in this research include ATL-1103, BIM-23A758, DG-3173, FP-002, G-02113, ISIS-GHRLRx, ITF-2984, L-779976, octreotide, octreotide acetate, octreotide acetate LAR, octreotide acetate long acting, octreotide acetate SR, octreotide SR, pasireotide LAR, pegvisomant, Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders, Somadex, SXN-101742 and SXN-101959.
The patient was maintained on octreotide acetate despite lack of uptake on octreotide scan.
Other drugs on the list include duloxetine (Cymbalta), under investigation for reports of urinary retention; octreotide acetate depot (Sandostatin LAR), under investigation for reports of ileus; and destlurane (Suprano, under investigation for reports of cardiac arrest.
Other drugs on the list include duloxetine (Cymbalta), under investigation for reports of urinary retention; octreotide acetate depot (Sandostation LAR), under investigation for reports of ileus; and desflurane (Suprane), under investigation for report of cardiac arrest.
Octreotide acetate is a synthetic somatostatin analogue that binds to somatostatin receptors on somatotroph tumors and inhibits GH synthesis and secretion.
1] Octreotide acetate for injectable suspension was approved by FDA for the treatment of carcinoid syndrome in 1998.
Acromegaly lanreotide acetate octreotide acetate Hormone Therapy Medroxyprogesterone Somatropin Infectious Disease Interferon Metabolic Exenatide Oncology Neoplastic Meningitis Cytarabine Prostate leuprolide acetate leuprolide acetate triptorelin pamoate Schizophrenia Fluphenazine Haloperidol paliperidone palmitate olanzapine risperidone Substance Abuse naltrexone Reproductive Health Estradiol valerate Depo-estradiol Depo-testosterone
Food and Drug Administration has granted tentative approval for the Company's Octreotide Acetate Injection, 50 mcg/mL, 100 mcg/mL and 500 mcg/mL in one-mL single-dose vials and 200 mcg/mL and 1000 mcg/mL in 5 mL multi-dose vials.
Tenders are invited for Supply of medicines for use of individual patients,inj docetaxel 120mg 1 nos,inj carboplatin450mg 1 nos,inj pegfilgrastim 6mg 1 nos,tab mycophenolate mofetil 500mg 720 nos,inj octreotide acetate 30 mg 1 nos,cap lycosafe 30 nos,tab everolimus5mg 30 nos,inj cisplatin 50mg 8 nos,inj cisplatin 10mg 8 nos,inj fosaprepitant 150mg 4 nos,inj pemetrexed 500mg 8 nos,colostomy bag -13986 (colopast) 24 nos,flange-13196 (coloplast) 24 nos,belt-0421 (coloplast) 6 nos,tab digemax 1100 nos,capd 1.
Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin).
Utilizing the Company's patented Hydron drug delivery platform, the implant has been developed to provide the continuous 6-month administration of octreotide acetate for treating acromegaly.